Dermatological treatment developer Dermira has now raised $128m, with pharmaceutical company UCB joining Maruho as a corporate backer.

Two researchers at the university have been awarded funding for their genomic prescribing system.

Global Corporate Venturing caught up with the three founding directors of insurance group MassMutual's corporate venturing unit to get the lowdown on their plans for the fund.

The cancer immunotherapy startup is rushing past $300m in funding.

A range of undisclosed private investors and high net-worth individuals took part in the round.

Corporates are funding healthcare companies at an earlier stage to get a foothold, and to offset R&D costs, Jonathan Norris from Silicon Valley Bank told Global Corporate Venturing.

Otonomy, which is developing treatments for ear disorders, could boost the size of the offering to $115m if the underwriters take up the option to buy more shares.

The pharmaceutical company has raised over $100m in equity funding from investors including Boehringer Ingelheim and Allergen.

Queen Mary University of London spin-out Retroscreen Virology places 12,293,077 ordinary shares.